Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Credit agrmnt [a]
Appointed CFO
Quarterly results
Director departure
CC transcript
Anika Therapeutics, Inc. (ANIK) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/08/2023 8-K Quarterly results
Docs: "Anika Reports Second Quarter 2023 Financial Results"
05/09/2023 8-K Quarterly results
Docs: "Anika Reports First Quarter 2023 Financial Results Positive Start to 2023 Revenue Growth with OA Pain Management Up 8% and Joint Preservation and Restoration Up 11%"
04/28/2023 8-K Quarterly results
04/13/2023 8-K Quarterly results
03/06/2023 8-K Quarterly results
Docs: "Anika Reports Fourth Quarter and Year-End Fiscal 2022 Financial Results"
11/08/2022 8-K Quarterly results
11/01/2022 8-K Quarterly results
08/03/2022 8-K Quarterly results
Docs: "Anika Reports Second Quarter Fiscal 2022 Financial Results"
06/10/2022 8-K Quarterly results
05/05/2022 8-K Quarterly results
03/08/2022 8-K Quarterly results
11/15/2021 8-K Credit agreement amendment
Docs: "THIRD AMENDMENT TO CREDIT AGREEMENT This THIRD AMENDMENT TO CREDIT AGREEMENT, dated as of November 12, 2021 , is entered into among ANIKA THERAPEUTICS, INC., a Delaware corporation , the Subsidiary Guarantors party hereto, each lender party hereto, and the Administrative Agent , and modifies that certain Credit Agreement, dated as of October 24, 2017 , among the Borrower, the Subsidiary Guarantors, the lenders from time to time party thereto , and BANK OF AMERICA, N.A., as administrative agent for the Lenders . Capitalized terms used herein and not defined herein shall have the meaning assigned to such terms in the Amended Credit Agreement. PRELIMINARY STATEMENTS"
11/04/2021 8-K Quarterly results
Docs: "Anika Reports Third Quarter 2021 Financial Results"
11/01/2021 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Anika Appoints Sheryl Conley to Board of Directors Appointment brings experienced orthopedic industry commercial leader to Anika’s Board"
08/05/2021 8-K Quarterly results
06/30/2021 8-K Other Events  Interactive Data
06/22/2021 8-K Quarterly results
05/06/2021 8-K Quarterly results
03/04/2021 8-K Quarterly results
11/04/2020 8-K Quarterly results
Docs: "Anika Reports Third-Quarter 2020 Financial Results"
10/21/2020 8-K Other Events, Financial Statements and Exhibits  Interactive Data
Docs: "Anika Announces FDA 510 Clearance for its WristMotion® Total Arthroplasty System for the Replacement of Painful Wrist Joints System designed to alleviate pain and restore function and mobility of the wrist joint BEDFORD, Mass., Oct. 21, 2020 -- Anika Therapeutics, Inc. , a global joint preservation company that creates and delivers meaningful advancements in early intervention orthopedic care, today announced that the Company’s WristMotion Total Arthroplasty System received 510 clearance from the U.S. Food and Drug Administration. The WristMotion Total Arthroplasty System is indicated for replacement of the painful wrist joint due to rheumatoid arthritis, osteoarthritis, or post-traumatic arthritis. “We are delighted to receive clearance for this innovative wrist device as it is another st..."
09/08/2020 8-K Quarterly results
08/05/2020 8-K Quarterly results
07/30/2020 8-K Quarterly results
06/18/2020 8-K Quarterly results
06/02/2020 8-K Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements...
Docs: "Anika Announces Planned CFO Transition"
05/07/2020 8-K Other Events
05/07/2020 8-K Quarterly results
04/29/2020 8-K Entry into a Material Definitive Agreement, Departure of Directors or Certain Officers; Election of Directors; Appointment of...
Docs: "Employment Agreement between Anika Therapeutics, Inc. and Cheryl R. Blanchard",
"Anika Names Cheryl R. Blanchard, Ph.D., as President and Chief Executive Officer"
04/08/2020 8-K Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant, Financial ...
Docs: "Anika Takes Actions to Strengthen Liquidity in Light of COVID-19 BEDFORD, Mass., April 08, 2020 -- Anika Therapeutics, Inc. , a global, integrated joint preservation and regenerative therapies company with products leveraging its proprietary hyaluronic acid technology platform, today provided an update on actions it is taking to strengthen liquidity in light of the COVID-19 pandemic. To strengthen its financial position, the Company is drawing down $50 million on its existing credit facility. Following the drawdown, the Company will have total liquidity of approximately $140 million, comprised of cash and investments on hand. The Company has no debt maturities through the end of 2020, and the credit facility matures in October 2022. The applicable interest rate under the credit facility is..."
03/13/2020 8-K/A Quarterly results
03/13/2020 8-K/A Quarterly results
03/02/2020 8-K Quarterly results
02/20/2020 8-K Quarterly results
  Next >>

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy